
Oxaliplatin Mylan 50 mg vial is a chemotherapy vial that contains the active ingredient oxaliplatin. Oxaliplatin is a platinum-based anticancer medicine often grouped with alkylating agents. It damages cancer-cell DNA and interferes with cell division, which helps slow or kill rapidly dividing cancer cells.
The verified product page for Oxaliplatin Mylan 50 mg vial on Vezeeta lists oxaliplatin as the active ingredient and describes it for advanced colon and rectal cancer.
| FeatureDetails | |
| Brand | Oxaliplatin Mylan |
| Active ingredient | Oxaliplatin |
| Strength discussed | 50 mg |
| Form | Vial for intravenous infusion preparation |
| Main use | Colon and colorectal cancer treatment as part of chemotherapy regimens |
Oxaliplatin is used with fluorouracil and leucovorin in adult patients for adjuvant treatment of stage III colon cancer after complete surgical removal of the tumor, and for treatment of advanced colorectal cancer. Treatment decisions depend on cancer stage, previous therapy, kidney function, blood counts, molecular testing when relevant, and the patient’s overall condition.
If you are comparing treatment options or need follow-up, you can book an oncologist on Vezeeta. Screening and evaluation of colon problems may also involve gastroenterology care; Vezeeta has medical content about colon polyps, which may be relevant to colorectal cancer prevention discussions.
The commonly referenced adult dose for colorectal cancer is 85 mg/m² by intravenous infusion over 120 minutes every 2 weeks, given with infusional fluorouracil and leucovorin. In stage III colon cancer after surgery, treatment may continue for up to 12 cycles, around 6 months, unless toxicity requires stopping. In advanced colorectal cancer, it may continue until disease progression or unacceptable toxicity.
The dose is calculated from body surface area, not simply body weight. The oncology team may reduce, delay or stop the dose for severe diarrhea, vomiting, low neutrophils, low platelets, neuropathy, severe kidney impairment or other toxicities. Oxaliplatin must be diluted and administered by trained healthcare professionals. It should not be mixed with saline or chloride-containing solutions and is commonly prepared in dextrose 5% because chloride-containing or alkaline solutions can affect platinum-compound stability.
Oxaliplatin Mylan is given by IV infusion, so it is not taken before or after food. Your doctor may prescribe anti-nausea medicines before chemotherapy. Eat as advised by your oncology team, and avoid cold drinks or ice around treatment if you develop cold-triggered nerve symptoms.
If you miss an infusion appointment, call your oncology center as soon as possible. Do not try to compensate by changing another medicine. Chemotherapy timing must be rearranged safely after checking blood counts and clinical status.
Oxaliplatin begins exposing cancer cells during the infusion, but patients usually cannot feel it working. Effectiveness is assessed by scans, tumor markers when appropriate, symptoms and the oncology plan after several cycles. Acute nerve symptoms and cold sensitivity can occur during treatment or within hours to two days after infusion and often improve within days to about two weeks, but repeated cycles can cause longer-lasting neuropathy.
Common side effects include tingling, numbness, burning or pain in the hands, feet, mouth or throat; cold sensitivity; nausea; vomiting; diarrhea; mouth sores; fatigue; loss of appetite; abdominal pain; anemia; low white blood cells; low platelets; raised liver enzymes; and infusion-site reactions. Some patients experience jaw tightness, throat discomfort or difficulty speaking when exposed to cold.
Seek urgent medical help for trouble breathing, throat tightness, chest pain, fainting, swelling of the face or tongue, widespread rash, fever, chills, persistent diarrhea, bleeding, black stools, severe weakness, seizures, sudden vision changes, irregular heartbeat, severe muscle pain, dark urine, or new unexplained cough or shortness of breath.
Oxaliplatin should not be used in patients with a history of hypersensitivity to oxaliplatin or other platinum-based medicines. Tell your doctor about kidney disease, liver problems, lung disease, active infection, bleeding problems, heart rhythm disorders, long QT syndrome, abnormal electrolytes, previous severe neuropathy or fertility concerns. Blood counts, kidney tests, liver tests and neurological symptoms are monitored before and during cycles.
Important interaction concerns include other medicines that suppress bone marrow, drugs that prolong the QT interval, and oral anticoagulants such as warfarin because bleeding and INR changes may occur. Live vaccines and strong immunosuppressive treatments may be unsuitable during chemotherapy. Always provide your oncology team with a full list of prescription medicines, over-the-counter drugs, vitamins and herbal products.
Oxaliplatin can harm an unborn baby. Pregnancy should be avoided during treatment. Women of reproductive potential generally need effective contraception during therapy and for 9 months after the final dose. Men with partners who may become pregnant generally need effective contraception during therapy and for 6 months after the final dose. Breastfeeding is not recommended during treatment and for 3 months after the final dose.
No. Oxaliplatin is not a daily medicine. It is usually given in cycles, commonly every 2 weeks, as part of a structured chemotherapy regimen. Long-term use is limited by benefit, cancer response and toxicity, especially neuropathy and blood-count suppression. Treatment may be stopped for disease progression, severe allergic reaction, severe neuropathy, serious lung toxicity, posterior reversible encephalopathy syndrome, rhabdomyolysis or other unacceptable adverse effects.
Alternatives depend on the cancer type, stage, biomarkers and previous treatments. Options may include other oxaliplatin brands or strengths, fluoropyrimidine-based regimens, irinotecan-based regimens, capecitabine combinations, targeted therapy or immunotherapy in selected patients. Do not substitute one chemotherapy product for another without the treating oncologist and oncology pharmacist.
The price of Oxaliplatin Mylan 50 mg vial in Egypt can change according to availability, pharmacy policy and official pricing updates. For the current availability and purchase details, check the verified Vezeeta pharmacy product page or ask a licensed pharmacist.
It is mainly used with fluorouracil and leucovorin for stage III colon cancer after surgery and for advanced colorectal cancer.
It is a platinum chemotherapy that disrupts DNA function in cancer cells, leading to cell damage and death.
It is given as an IV infusion, commonly over 2 hours, under supervision in a chemotherapy unit.
Some effects, such as nausea or acute cold sensitivity, may improve within days. Neuropathy can last longer and may persist after treatment, especially after repeated cycles.
Use prescribed anti-nausea medicines, avoid cold drinks and cold objects, report symptoms early, attend blood tests and follow dose-adjustment instructions from your oncology team.
Acute cold sensitivity often appears during or soon after infusion and may improve within several days to about 14 days, but it can recur with later cycles.
Effectiveness depends on cancer stage, regimen, molecular profile and overall health. It is a standard component of several colorectal cancer chemotherapy plans.
Leucovorin is used to enhance the effect of fluorouracil in the regimen. It is not given to make oxaliplatin itself stronger.
It may be stopped for cancer progression, severe neuropathy, serious allergy, severe blood toxicity, confirmed serious lung disease or other unacceptable toxicity.
Platinum-related compounds have a long terminal elimination phase; a large portion is eliminated in urine within days, while inactive platinum conjugates can persist longer.
Oxaliplatin is not compatible with chloride-containing solutions such as normal saline, so dextrose 5% is commonly used for final dilution according to product instructions.
The dose is commonly calculated by body surface area in mg/m², then adjusted for toxicity, kidney function and treatment protocol.
The information in this article is provided for general health education and does not replace medical advice from a doctor or pharmacist. Do not start, stop, or change the dose of any medication without consulting a qualified healthcare professional.
Consultant in Oncology ,Hematology and Nuclear Medicine, Al-Azhar Medicine
Lecturer Clinical Oncology Faculty of Medicine Alexandria University
Consultant and MD in Oncology and Nuclear Medicine, Cairo University, Kasr Al-Ainy
Consultant in Oncology ,Hematology and Nuclear Medicine, Al-Azhar Medicine
Lecturer Clinical Oncology Faculty of Medicine Alexandria University
Consultant and MD in Oncology and Nuclear Medicine, Cairo University, Kasr Al-Ainy